SBIR Phase I:Commercial Scale-up of Algal Fermentation Processes to Manufacture Eicosapentaenoic Acid

Award Information
Agency:
National Science Foundation
Amount:
$150,000.00
Program:
SBIR
Contract:
1013471
Solitcitation Year:
2010
Solicitation Number:
NSF 09-609
Branch:
N/A
Award Year:
2010
Phase:
Phase I
Agency Tracking Number:
1013471
Solicitation Topic Code:
BC
Small Business Information
Algisys
6610 Hidden Woods Trail, Cleveland, OH, 44143
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
832412592
Principal Investigator
 Charles Roe
 PhD
 (440) 684-0980
 charles@algisys.com
Business Contact
 Charles Roe
Title: PhD
Phone: (440) 684-0980
Email: charles@algisys.com
Research Institution
N/A
Abstract
This Small Business Innovation Research (SBIR) Phase I project is focused on completing the research necessary to begin commercializing the production of eicosapentaenoic acid (EPA) from algae. Algisys, LLC has partnered with Virginia Tech to further develop patent-pending technology for the production of EPA via algal fermentation, using inexpensive biodiesel-derived crude glycerol as a feedstock. This SBIR project is expected to result in the technical data necessary to initiate scale-up work on a process to convert waste glycerol into a high value nutritional oil containing EPA. Algisys plans to be the first company in the world to commercially produce EPA directly from algae. The broader/commercial impacts of this research involve the creation of a completely new source of EPA, which is currently derived solely from the oil of select types of marine fish. Fish oil contains low levels of omega-3 fatty acids, such as EPA, due to the consumption of algae by fish as part of the marine food chain. Omega-3s represent a multi-billion dollar market and are essential in the human diet for proper growth, development, and good health. Over 8,000 scientific studies and 40 years of research have shown that omega-3s have significant health benefits, and can be used to prevent/treat a variety of disorders: cardiovascular diseases, arthritis/inflammatory diseases, immune system disorders, Alzheimer?s, and macular degeneration. Algisys intends to help meet the rapidly growing demand for EPA using patent-pending technology that merits further development, and is believed to be both scalable and cost effective.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government